Ngā hua rapu - Max Sauter

  • E whakaatu ana i te 1 - 6 hua o te 6
Whakamahine hua
  1. 1
    Radiolabeling Strategies for Tumor-Targeting Proteinaceous Drugs

    Radiolabeling Strategies for Tumor-Targeting Proteinaceous Drugs mā Grant Sugiura, Helen Kühn, Max Sauter, Uwe Haberkorn, Walter Mier

    I whakaputaina 2014
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Effect of Staggered vs. Simultaneous Co-Administration of Bempedoic Acid on Pharmacokinetics of Pravastatin: Randomized, Cross-Over Clinical Trial in Healthy Volunteers

    Effect of Staggered vs. Simultaneous Co-Administration of Bempedoic Acid on Pharmacokinetics of Pravastatin: Randomized, Cross-Over Clinical Trial in Healthy Volunteers mā Felicitas Stoll, Salvatore Amato, Max Sauter, Jürgen Burhenne, Johanna Weiß, Walter E. Haefeli, Antje Blank

    I whakaputaina 2025
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Identification of a Novel ITGαvβ6-Binding Peptide Using Protein Separation and Phage Display

    Identification of a Novel ITGαvβ6-Binding Peptide Using Protein Separation and Phage Display mā Annette Altmann, Max Sauter, Saskia Roesch, Walter Mier, Rolf Warta, Jürgen Debus, Gerhard Dyckhoff, Christel Herold‐Mende, Uwe Haberkorn

    I whakaputaina 2017
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Comparison of the RGD Motif–Containing α<sub>v</sub>β<sub>6</sub> Integrin–Binding Peptides SFLAP3 and SFITGv6 for Diagnostic Application in HNSCC

    Comparison of the RGD Motif–Containing α<sub>v</sub>β<sub>6</sub> Integrin–Binding Peptides SFLAP3 and SFITGv6 for Diagnostic Application in HNSCC mā Saskia Roesch, Thomas Lindner, Max Sauter, Anastasia Loktev, Paul Flechsig, Martin Müller, Walter Mier, Rolf Warta, Gerhard Dyckhoff, Christel Herold‐Mende, Uwe Haberkorn, Annette Altmann

    I whakaputaina 2018
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC

    Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC mā Xu Zhou, Jingyu An, Roma Kurilov, Benedikt Brors, Kai Hu, Teresa Peccerella, Stephanie Roessler, Katrin Pfütze, Angela Schulz, Stephan Wolf, Nicolas Hohmann, Dirk Theile, Max Sauter, Jürgen Burhenne, Shigenori Ei, Ulrike Heger, Oliver Strobel, Simon T. Barry, Christoph Springfeld, Christine Tjaden, Frank Bergmann, Markus W. Büchler, Thilo Hackert, Franco Fortunato, John P. Neoptolemos, Peter J. Bailey

    I whakaputaina 2023
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models

    The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models mā Romain Sigaud, Lisa Rösch, Charlotte Gatzweiler, Julia Benzel, Laura von Soosten, Heike Peterziel, Florian Selt, Sara Najafi, Simay Ayhan, Xenia F. Gerloff, Nina Hofmann, Isabel Büdenbender, Lukas Theo Schmitt, Kathrin I. Foerster, Jürgen Burhenne, Walter E. Haefeli, Andrey Korshunov, Felix Sahm, Cornelis M. van Tilburg, David Jones, Stefan M. Pfister, Deborah Knoerzer, Brent Kreider, Max Sauter, Kristian W. Pajtler, Marc Zuckermann, Ina Oehme, Olaf Witt, Till Milde

    I whakaputaina 2022
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: